BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VX-770: Phase III data

The double-blind, international Phase III STRIVE trial in 161 patients ages 12 and up carrying the G551D mutation in CFTR on at least 1 allele showed that twice-daily 150 mg oral VX-770 met the primary endpoint of significantly improving the mean absolute change in FEV1 from baseline to week 24 vs. placebo. Specifically, the mean absolute improvement in FEV1 at week 24 compared to placebo was 10.6% (p<0.0001). VX-770 also met the secondary endpoints of significantly improving the...

Read the full 366 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >